Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062469 | 0.88 | NOTUM (0.55) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14804393 | 0.85 | NPC1 (0.56) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12844628 | 0.85 | MAPT (0.47) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL9060124 | 0.83 | GPR84 (0.47) | NOTUMNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL19948855 | 0.83 | GPR84 (0.43) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL25975967 | 0.83 | AOC3 (0.49) | NOTUMNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL13592787 | 0.82 | HSD11B1 (0.50) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| Hydrochloric Acid SCHEMBL25430361 | 0.81 | AOC3 (0.48) | NOTUMNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL762899 | 0.81 | NPC1 (0.65) | NOTUMNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8246436 | 0.80 | KDM4E (0.42) | NOTUMNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024141925-A1 | COMPOSITIONS FOR PREVENTING AND TREATING RENAL FAILURE (RF) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | WO | disclosed |
| WO-2023144737-A1 | COMPOSITIONS FOR PREVENTING OR TREATING HEART FAILURE (HF) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144736-A1 | COMPOSITIONS FOR PREVENTING OR TREATING PULMONARY ARTERIAL HYPERTENSION | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023031775-A1 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-03-09 | — | — | WO | disclosed |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | IMMUNOGEN, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020081689-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-2861649-B1 | SULFONATED NAPHTHALENE POLYOXADIAZOLE POLYMERS | DU PONT (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2017018803-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| US-8362004-B2 | Piperazine analogs as broad-spectrum influenza antivirals | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238539-A1 | NOVEL PIPERAZINE ANALOGS AS BROAD-SPECTRUM INFLUENZA ANTIVIRALS | ZC3HAV1, ZC3HAV1L, HCRTR1 | NOTUM 3982/4885NPC1 912/4885RAB9A 2247/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | NOTUM 2412/4885NPC1 1789/4885RAB9A 1585/4885 |
| US-20220133711-A1 | CAMPTOTHECIN DERIVATIVES | TOP2A, TOP2B, PCNA | NOTUM 4058/4885NPC1 1349/4885RAB9A 911/4885 |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | NOTUM 2003/4885NPC1 858/4885RAB9A 1826/4885 |
| US-20210347772-A1 | AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 | LRRK2, PARK7, GDI2 | NOTUM 3570/4885NPC1 1367/4885RAB9A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.